Solarvest Provides Corporate Update December 2020

- December 18th, 2020

TheNewswire – December 18 th 2020  Solarvest BioEnergy Inc. Solarvest, is pleased to provide this operational update. Solarvest has recently incorporated Eversea TM America Inc a US legal entity.  This Florida based, 100% wholly owned subsidiary will soon manage the platform for the Company’s organic Omega-3 products.   The division will be focused on the marketing and sales of Eversea branded nutraceuticals, …

(TheNewswire)

TheNewswire – December 18 th 2020  Solarvest BioEnergy Inc. (“Solarvest”, or the “Company”) (TSXV:SVS), Solarvest, is pleased to provide this operational update.

Solarvest has recently incorporated Eversea TM America Inc a US legal entity.  This Florida based, 100% wholly owned subsidiary will soon manage the platform for the Company’s organic Omega-3 products.   The division will be focused on the marketing and sales of Eversea branded nutraceuticals, organic DHA food additive powder and house branded supplements for strategic and complementary companies selling into the rapidly growing organic and natural foods oriented market.

New Patents

Solarvest has received a patent for its organic Omega-3 from the Australian Patent office, extending its robust intellectual property portfolio. As well, the Company has now been granted a US Algae Expression Systems 2nd Divisional Application which will further protect its protein expression system. Solarvest’s proven technical ability to generate high value bioactive therapeutic proteins and active ingredients for the pharma, nutraceutical and food supplements sectors has now culminated in the development and launch of its first nutraceutical offering.

Dr Edward Brennon has resigned from the Board of Directors. The company thanks him for his valuable input and leadership.

About Solarvest

Solarvest BioEnergy Inc. is an algae biologics company whose production platform provides it with an extremely flexible system capable of producing numerous products from Omega 3 fatty acids to human therapeutic proteins. The company has successfully demonstrated the expression of BMP, a high value therapeutic protein, viral antigens (immune stimulating proteins), and Cecropins (antimicrobial peptide/protein). The company has initiated a program for the expression of CBD and THC to be produced in GMP fermentation facilities.

For further information contact:

Email: invest@solarvest.ca

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Statements made in this news release may contain forward-looking statements that may involve a number of risks and uncertainties.  Actual events or results could differ materially from the Company’s expectations and projections.

Copyright (c) 2020 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

  Life Science and Healthcare Investing report cover

Life Science and Healthcare Investing in 2021

 
The life science and healthcare market is a booming, multi-billion dollar industry. Read our 2021 life science outlook report!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select None
Select All

Tags

Leave a Reply